hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06279455 id: E-74555795-050.01.04-392120 briefTitle: Pelvic Floor Muscle Exercise During Pregnancy overallStatus: COMPLETED date: 2022-12-05 date: 2023-03-06 date: 2023-10-30 date: 2024-02-28 date: 2024-04-03 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: This study was conducted to evaluate the effects of pelvic floor muscle exercises during pregnancy on sexual function, lower urinary tract symptoms and birth process. The research was conducted with pregnant women who applied to the Pregnancy Outpatient Clinic of Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine Hospital. Power analysis was performed to determine the number of samples to be included in the study. It was determined that 29 pregnant women should be included in each group (experimental and control). Considering the possibility of data loss, 50 pregnant women were included in each group. As a result of the exclusion of 8 women who withdrew from participating in the study, 5 women due to risky pregnancies (bleeding, preeclampsia and gestational diabetes) and 17 women due to cesarean delivery, the data of 35 pregnant women in the experimental group and 35 pregnant women in the control group were obtained. Pregnant women in the experimental group were gestational aged 18-20. Two sessions of training were given on female reproductive and urinary system anatomy, physiological changes during pregnancy and their effects on sexual life, and pelvic floor muscle exercises, using the "Pelvic Floor Health \& Sexual Life Training Booklet during Pregnancy" and the pelvic floor muscle exercise training video developed by the researcher between the weeks of pregnancy. Pregnant women were asked to perform pelvic floor muscle exercises, 3 sets a day, 3 days a week, for 12 weeks, starting from the 20th week of pregnancy, and record them in the Pelvic Floor Muscle Exercise Follow-up Form created by the researcher. Pregnant women in the control group were not given any training and were routinely monitored in the outpatient clinic. Pregnant women who apply to the outpatient clinic are examined by nurses, with their vital signs taken and anamnesis taken by the physician. Recommendations are made regarding the complaints of pregnant women. Non-stress tests are routinely applied to pregnant women who are at the 36th week of pregnancy and above. conditions: Lower Urinary Tract Symptoms conditions: Sexual Function studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Pelvic Floor Muscle Exercise Group primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 70 type: ACTUAL name: Pelvic Floor Muscle Exercise measure: Sexual Function measure: Lower Urinary Tract Symptoms measure: Birth Process sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Istanbul University-Cerrahpasa city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06279442 id: LACOG 0723 briefTitle: Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-08 date: 2025-08 date: 2024-02-28 date: 2024-02-28 name: Latin American Cooperative Oncology Group class: OTHER briefSummary: This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites. conditions: Carcinoma Adrenal conditions: Carcinoma, Adrenocortical Recurrent studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 150 type: ESTIMATED measure: Demographic and Clinical Characterization of Adrenocortical Carcinoma in Brazil measure: Assessment of the Association Between Clinical, Pathological, Epidemiological Factors, and Therapeutic Modalities with Prognosis and Outcomes such as Overall Survival or Recurrence-Free Survival measure: Evaluating the Impact of Adjuvant Mitotane Use on Progression-Free Survival and Overall Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: A.C. Camargo Cancer Center city: São Paulo zip: 01.509-001 country: Brazil name: Milena Shizue Tariki role: PRINCIPAL_INVESTIGATOR lat: -23.5475 lon: -46.63611 hasResults: False
nctId: NCT06279429 id: KTGH11137 briefTitle: Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia overallStatus: RECRUITING date: 2022-05-31 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-29 name: Kuang Tien General Hospital class: OTHER briefSummary: Insomnia or sleep disturbance is a common disorder in patients with chronic kidney disease (CKD), but is often unrecognized and undertreated. It is known that sleep disorders may indirectly cause a variety of diseases and affect quality of life. The most common sleep disorders that occur in CKD are insomnia, excessive daytime sleepiness, obstructive or central sleep apnea (SA), and sleep disorders. This study evaluates the effectiveness and safety of Sideral® Sucrosomial Iron and iron chewable tablets 100mg commonly used in health insurance on sleep disorders in patients with CKD and iron deficiency anemia. conditions: CKD conditions: Sleep Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Sideral® Sucrosomial Iron name: Iron chewable tablet measure: Insomnia Severity Index (ISI) measure: Pittsburgh Sleep Quality Index (PSQI) measure: Epworth sleepiness Scale (ESS) measure: Hemoglobin measure: Ferritin measure: Serum Iron measure: Transferrin Saturation measure: Erythrocyte sedimentation rate sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kuang Tien General Hospital status: RECRUITING city: Taichung zip: 433 country: Taiwan name: Nai-Hwei Wang, MD role: CONTACT phone: 886426885599 email: fengcheese@gmail.com name: Chun-Pai Yang, MD role: PRINCIPAL_INVESTIGATOR lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06279416 id: 2023-31 briefTitle: Expected Difficult Airway Management overallStatus: RECRUITING date: 2023-12-30 date: 2024-12 date: 2024-12 date: 2024-02-28 date: 2024-03-08 name: Kocaeli City Hospital class: OTHER_GOV briefSummary: In this study, the investigators will evaluate the advanced airway methods applied in the anesthesiology and reanimation clinic of the hospital to patients who met the criteria for awake intubation specified in the ASA 2022 difficult airway management guideline or who could not be intubated after induction of anesthesia in another center. The advanced airway method applied to the difficult airway patient expected in the operating room, the duration, success and complications of the method will be observed and recorded. conditions: Awake Intubation conditions: Advanced Airway Techniques studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 108 type: ESTIMATED name: fiberoptic intubation name: laryngeal mask airway-mediated aintree catheter name: videolaryngoscopy measure: Comparison of advanced airway methods in the awake patient with difficult airway. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kocaeli City Hospital status: RECRUITING city: Kocaeli country: Turkey lat: 39.62497 lon: 27.51145 hasResults: False
nctId: NCT06279403 id: IIT-2023-0277 briefTitle: Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2029-03-01 date: 2024-02-28 date: 2024-02-28 name: RenJi Hospital class: OTHER briefSummary: Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
Interventions: Eligible participants will receive upfront treatment with a combination of Axitinib and Toripalimab for 4 cycles. After 2 cycles of treatment, radiological assessment will be conducted using RECIST 1.1 criteria. If disease progression is observed, the clinical trial will be terminated, and second-line treatment will be initiated according to guidelines. If disease progression is not observed, treatment will continue for 2 additional cycles followed by repeat radiological assessment before undergoing surgery. conditions: Clear-cell Metastatic Renal Cell Carcinoma conditions: Immune Checkpoint Inhibitors conditions: Cytoreductive Nephrectomy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Toripalimab name: Cytoreductive Nephrectomy name: Axitinib measure: Pathological Major Response (MPR) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279390 id: 202305126RINC briefTitle: PRE-DELIRIC Prediction Model Plus SMART Care to Reduce the Incidence of Delirium in ICU Patients overallStatus: COMPLETED date: 2023-06-08 date: 2023-10-30 date: 2023-10-30 date: 2024-02-28 date: 2024-02-28 name: National Taiwan University Hospital class: OTHER briefSummary: Delirium is a severe acute brain dysfunction characterised by sudden confusion, inattention and fluctuating level of consciousness, which mainly affects intubated intensive care patients. It increases the risk of self-extubation, prolongs ICU stay and increases mortality. The incidence of delirium in ICUs varies, with approximately 33.3% of patients affected, and rates of new-onset and pre-existing delirium range from 4% to 89%. Accurate diagnosis is challenging, with 60-80% of patients remaining undiagnosed. Early detection is critical for intervention and improved outcomes.
To address these issues, the PREdiction of DELIRium (PRE-DELIRIC) model incorporates 10 risk factors and predicts delirium within 24 hours of ICU admission, allowing risk stratification into low to very high risk categories. It recalibrates predictive values with a sensitivity of 91.3% and specificity of 64.4% using a cut-off score of 27%. However, its integration into delirium management is underexplored. Delirium risk stratification supports efficient resource allocation, cost control, workload reduction and ethical care, while promptly identifying high-risk patients.
In this study, Investigators evaluate the integration of the PRE-DELIRIC model into a comprehensive delirium management approach called PRE-DELIRIC-guided SMART/SmART care. SMART care includes improving familiarity, assessing pain and anxiety, reducing equipment discomfort and cognitive stimulation. Patients with PRE-DELIRIC scores \>30% receive SMART care and multidisciplinary involvement, based on the American Delirium Society. conditions: Intensive Care Unit Delirium studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 381 type: ACTUAL measure: the incidence of delirium measure: duration of ventilator use measure: rate of unplanned self-extubation measure: day of physical restraint measure: level of mobility measure: cumulative dose of sedatives sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Taiwan University Hospital city: Taipei zip: 100 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06279377 id: Katip Celebi University briefTitle: Examining the Effectiveness of Exercise Training After Cervical Laminoplasty Surgery overallStatus: RECRUITING date: 2023-05-05 date: 2024-09-15 date: 2025-05-15 date: 2024-02-28 date: 2024-02-28 name: Izmir Katip Celebi University class: OTHER briefSummary: The goal of this clinical trial is to compare the effects of the stabilization exercise program applied after cervical laminoplasty surgery compared to standard exercise on pain, dysfunction, normal joint movement, proprioception, balance, muscle endurance, postural alignment and related factors (kinesiophobia, awareness, quality of life, disability, physical activity level). The main question\[s\] it aims to answer are:
Patients will start their first exercise session on the day they will be discharged from the hospital. Patients in both exercise groups will be provided with cervical normal joint movement (ROM), posture and patient education on the day of discharge. They will be asked to do posture exercises and neck exercises under the guidance of a physiotherapist. Patients in the stabilization exercise group (experiment) will undergo stabilization exercises under the supervision of a physiotherapist, in addition to the practices in the standard exercise group. Both groups will do a warm-up program before exercise and a cool-down program afterwards. Patients will be asked to do the exercises face to face with a physiotherapist 3 days a week. The first evaluations will be made on the day they come to the outpatient clinic for examination before surgery. Post-surgical evaluations will be made routinely after the exercise program is completed, when they are called by the physician for a check-up (6th week).
Researchers will compare the standard exercise group with the stabilization exercise group to see if pain, dysfunction, normal joint movement, proprioception, balance, muscular endurance, postural alignment and related factors (kinesiophobia, awareness, quality of life, disability, physical activity level) are different. conditions: Cervical Spine Disease conditions: Surgery conditions: Rehabilitation conditions: Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Stabilization Exercises name: Standard Exercises measure: Pain intensity measure: Dysfunction measure: Joint Range of Motion measure: Proprioception measure: Balance measure: Neck Extensor Muscle Endurance measure: Neck Flexor Muscles Endurance measure: Postural Alignment measure: Kinesiophobia measure: Neck Awareness measure: Life Quality measure: Disability measure: Physical Activity Level measure: Sociodemographic İnformation measure: Sociodemographic İnformation BMI measure: Health-related Habits measure: Dominant Side sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Izmir Katip Celebi University Ataturk Education and Research Hospital status: RECRUITING city: İzmir country: Turkey name: Hasan Kamil SUCU, Prof. Dr. role: CONTACT name: Hilal UZUNLAR, MSc, RC role: PRINCIPAL_INVESTIGATOR name: Sevtap GUNAY UCURUM, Assoc. Dr. role: PRINCIPAL_INVESTIGATOR name: Ismail Ertan SEVİN, Prof. Dr. role: SUB_INVESTIGATOR lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06279364 id: SKB264-Ⅲ-11 briefTitle: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2026-07 date: 2026-07 date: 2024-02-28 date: 2024-02-28 name: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. class: INDUSTRY briefSummary: The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomised in a 1:1 ratio to one of two intervention groups. primaryPurpose: TREATMENT masking: NONE count: 524 type: ESTIMATED name: SKB264 name: Paclitaxel name: Nab-paclitaxel name: Capecitabine name: Eribulin name: Carboplatin measure: Overall Survival (OS) measure: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) measure: Progression-Free Survival (PFS) assessed by Investigator measure: Disease control rate (DCR) measure: Time to Response (TTR) measure: Adverse events(AEs) and severe adverse events (SAEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center city: Shanghai state: Shanghai country: China name: Zhimin Shao role: CONTACT email: szm@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06279351 id: Thalicolorectal briefTitle: Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Xinqiao Hospital of Chongqing class: OTHER name: Chongqing Medical University briefSummary: 1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.
2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies. conditions: Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Thalidomide+cetuximab+FOLFOX/FOLFIRI measure: ETS measure: ORR measure: DCR measure: PFS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279338 id: [2023] No.0969 briefTitle: A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-01-31 date: 2026-01-31 date: 2024-02-28 date: 2024-02-28 name: Wuhan Union Hospital, China class: OTHER briefSummary: Figure out the Efficacy and Safety of Azacitidine Combined with BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome with Moderate High IPSS-M Score conditions: Myelodysplastic Syndromes studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Azacitidine Injection measure: Progression-free survival (PFS) at 18 months post-transplant, month measure: Overall survival (OS) at 18 months post-transplant, month sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279325 id: C.I. PI23/637 briefTitle: Effects of a Computerized Cognitive Stimulation Intervention Adapted to the Level of Cognitive Reserve overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-31 date: 2025-01-15 date: 2024-02-28 date: 2024-02-28 name: Universidad de Zaragoza class: OTHER briefSummary: Normal ageing presents subtle cognitive changes that can be detected before meeting the criteria for Mild cognitive impairment (MCI). Older people with low cognitive reserve and who receive limited cognitive stimulation are at greater risk of deterioration. In this regard, cognitive stimulation (CS) has been identified as an intervention that reduces this risk, provided that its design considers the differences in the level of cognitive reserve (CR) acquired throughout life and the baseline level of cognitive functioning. The general objective of this study is to evaluate, through a randomized clinical trial, the effectiveness of a computerized cognitive stimulation program, designed and adapted from Occupational Therapy based on the level of cognitive reserve in older adults in Primary Care. 100 participants will be randomized in a stratified manner according to the level of cognitive reserve (high/low), assigning 50 participants to the control group and 50 participants to the intervention group. The intervention group will carry out a computerized cognitive stimulation intervention designed and adapted from occupational therapy according to the level of cognitive reserve, through the "stimulus" platform. The main result expected to be achieved is the improvement of higher brain functions. As secondary results, the investigators expect that those cognitive aspects most vulnerable to ageing will decrease more slowly (in areas such as memory, executive function, attention and processing speed) and that the cognitive reserve of the participants will increase, in addition to being able to balance gender differences in these aspects. The investigators think that these results can positively impact the creation of adapted, meaningful and stimulating CS programs in older adults to prevent MCI and experience healthier ageing. conditions: Mild Cognitive Impairment conditions: Cognitive Dysfunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Computerized cognitive stimulation program name: Face-to-face training-explanatory session measure: MEC-35 (Spanish version of Folstein's Mini-Mental) measure: Cognitive Reserve Questionnaire (CRQ) measure: Set-Test measure: The SDMT or Symbols and Digits Test measure: Color Word Stroop Test (CWST) measure: Verbal Learning Test (TAVEC) measure: Mobile Device Proficiency Questionnaire in Short Form (MDPQ-16) sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279312 id: N202311065 briefTitle: The Effect of Adaptogen Elixir on Sleep Improvement overallStatus: RECRUITING date: 2024-02-26 date: 2024-07-31 date: 2024-12-31 date: 2024-02-28 date: 2024-03-15 name: TCI Co., Ltd. class: INDUSTRY briefSummary: This study aims to examine the effectiveness of Adaptogen Elixir herbal drink in relieving emotions and improving sleep quality. Participants will be randomly assigned to either the placebo group or the Adaptogen Elixir herbal drink group, with 25 participants in each group. On the day of the experiment (week 0), participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them continuously for 4 weeks following the instruction. Follow-up assessments will be conducted in the 2nd and 4th weeks, participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. conditions: Sleep Disorder conditions: Anxiety Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: Placebo drink name: Adaptogen Elixir drink measure: Sleep monitoring measure: Sleeping qualityy measure: Sleeping disorders measure: Neuropeptide Y concentration measure: Cortisol concentration measure: Anxiety measure: Low Frequency/High Frequence (LF/HF) ratio sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Medical University status: RECRUITING city: Taipei country: Taiwan name: Hsin-Chien Lee, Doctor role: CONTACT phone: +886-02-22490088 phoneExt: 79213/8158 email: ellalee@tmu.edu.tw lat: 25.04776 lon: 121.53185 hasResults: False